Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced CancersPatricia LoRusso, Alejandro D. Ricart, Lisle M. Nabell et al.|Clinical Cancer Research|2010Cited by 250